Compare Tripadvisor Inc Common Stock (TRIP) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tripadvisor Inc Common Stock vs Viatris Inc — how do they compare? Tripadvisor Inc Common Stock trades at $13.82 (market cap $1.68B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 11.8× Tripadvisor Inc Common Stock's market cap, and Viatris Inc pays a 2.83% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| TRIP | VTRS | |
|---|---|---|
Market Cap | $1.68B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $19.14 | $17.39 |
52-Week Low | $9.24 | $8.74 |
Enterprise Value | $1.80B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tripadvisor (TRIP) trades at $13.8, down 5.35% over 24 hours. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators are neutral. Fundamentally, revenue grew to $1.89B in 2025 with a net income margin of 0.99%, but recent earnings misses and a high P/E of 131.09 raise valuation concerns. The recent $700M sale of TheFork to American Express simplifies the business and provides a cash infusion.
Outlook is mixed: the sale of TheFork and focus on core experiences offer strategic clarity, but stiff competition and macroeconomic pressures pose risks. Analyst consensus is a 'Hold' with a $13.87 price target, slightly above the current price, indicating limited near-term upside amid cautious sentiment.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
